Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.
Journal
Nature reviews. Rheumatology
ISSN: 1759-4804
Titre abrégé: Nat Rev Rheumatol
Pays: United States
ID NLM: 101500080
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
06
09
2022
pubmed:
6
10
2022
medline:
28
10
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of advanced cancers. Designed to enhance the antitumour immune response, they can also cause off-target immune-related adverse events (irAEs), which are sometimes severe. Although the efficacy of ICIs suggests that they could have wide-ranging benefits, clinical trials of the drugs have so far excluded patients with pre-existing autoimmune disease. However, evidence is accumulating with regard to the use of ICIs in this 'at-risk' population, with retrospective data suggesting that they have an acceptable safety profile, but that there is a risk of disease flare or other irAE occurrence. The management of immunosuppressive drugs at ICI initiation in patients with autoimmune disease (or later in instances of disease flare or irAE) remains a question of particular interest in clinical practice, in which there is always a search for the balance between protecting against autoimmunity and ensuring a good tumour response. Although temporary use of immunosuppressants seems safe, prolonged use or use at ICI initiation might hamper the antitumour immune response, prompting clinicians to use the minimal efficient immunosuppressive regimen. However, a new paradigm is emerging, in which inhibitors of TNF or IL-6 could have synergistic effects with ICIs on tumour response, while also preventing severe irAEs. If confirmed, this 'decoupling' effect on toxicity and efficacy could change therapeutic practice in this field. Knowledge of the current use of ICIs in patients with pre-existing autoimmune disease, particularly with regard to the use of immunosuppressive drugs and/or biologic DMARDs, can help to guide clinical practice.
Identifiants
pubmed: 36198831
doi: 10.1038/s41584-022-00841-0
pii: 10.1038/s41584-022-00841-0
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Immune Checkpoint Inhibitors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
641-656Informations de copyright
© 2022. Springer Nature Limited.
Références
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
pubmed: 29320654
doi: 10.1056/NEJMra1703481
Manson, G. et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J. Immunother. Cancer 7, 337 (2019).
pubmed: 31796119
pmcid: 6892018
doi: 10.1186/s40425-019-0821-8
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A. & Suarez-Almazor, M. E. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann. Intern. Med. 168, 121–130 (2018).
pubmed: 29297009
doi: 10.7326/M17-2073
Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
pubmed: 28855077
doi: 10.1016/S0140-6736(17)32247-X
Nocturne, G. & Mariette, X. B cells in the pathogenesis of primary Sjögren syndrome. Nat. Rev. Rheumatol. 14, 133–145 (2018).
pubmed: 29416129
doi: 10.1038/nrrheum.2018.1
Franks, A. L. & Slansky, J. E. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer. Res. 32, 1119–1136 (2012).
pubmed: 22493341
pmcid: 3349285
Askling, J. et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414–1420 (2005).
pubmed: 15843454
pmcid: 1755232
doi: 10.1136/ard.2004.033241
Dreyer, L. et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides — a follow-up study from the DANBIO Registry. Ann. Rheum. Dis. 72, 79–82 (2013).
pubmed: 22945500
doi: 10.1136/annrheumdis-2012-201969
Mercer, L. K. et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann. Rheum. Dis. 76, 497–503 (2017).
pubmed: 27502891
doi: 10.1136/annrheumdis-2016-209389
Mercer, L. K. et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann. Rheum. Dis. 74, 1087–1093 (2015).
pubmed: 24685910
doi: 10.1136/annrheumdis-2013-204851
Seror, R. & Mariette, X. Malignancy and the risks of biologic therapies: current status. Rheum. Dis. Clin. North. Am. 43, 43–64 (2017).
pubmed: 27890173
doi: 10.1016/j.rdc.2016.09.006
Mariette, X. et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann. Rheum. Dis. 70, 1895–1904 (2011).
pubmed: 21885875
doi: 10.1136/ard.2010.149419
De Cock, D. & Hyrich, K. Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best. Pract. Res. Clin. Rheumatol. 32, 869–886 (2018).
pubmed: 31427060
doi: 10.1016/j.berh.2019.03.011
Lopez-Olivo, M. A. et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308, 898–908 (2012).
pubmed: 22948700
doi: 10.1001/2012.jama.10857
Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316–326 (2022).
pubmed: 35081280
doi: 10.1056/NEJMoa2109927
Manger, B. & Schett, G. Rheumatic paraneoplastic syndromes — a clinical link between malignancy and autoimmunity. Clin. Immunol. 186, 67–70 (2018).
pubmed: 28736272
doi: 10.1016/j.clim.2017.07.021
Moinzadeh, P. et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res. Ther. 16, R53 (2014).
pubmed: 24524733
pmcid: 3978927
doi: 10.1186/ar4486
Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152–157 (2014).
pubmed: 24310608
doi: 10.1126/science.1246886
Yadav, S. et al. Autoantibodies as diagnostic and prognostic cancer biomarker: detection techniques and approaches. Biosens. Bioelectron. 139, 111315 (2019).
pubmed: 31132724
doi: 10.1016/j.bios.2019.111315
Gajewski, T. F., Fuertes, M., Spaapen, R., Zheng, Y. & Kline, J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 23, 286–292 (2011).
pubmed: 21185705
doi: 10.1016/j.coi.2010.11.013
Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547 (1995).
pubmed: 7584144
doi: 10.1016/1074-7613(95)90125-6
Matsumura, N., Ohtsuka, M., Kikuchi, N. & Yamamoto, T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm. Venereol. 96, 259–260 (2016).
pubmed: 26270860
doi: 10.2340/00015555-2212
Huang, C. et al. Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. J. Autoimmun. 104, 102333 (2019).
pubmed: 31564474
doi: 10.1016/j.jaut.2019.102333
Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).
pubmed: 33580222
doi: 10.1038/s41571-021-00473-5
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
pubmed: 34986285
doi: 10.1056/NEJMoa2109970
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Hirsch, L., Zitvogel, L., Eggermont, A. & Marabelle, A. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br. J. Cancer 120, 3–5 (2019).
pubmed: 30413824
doi: 10.1038/s41416-018-0294-4
Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022).
pubmed: 34818112
doi: 10.1200/JCO.21.02229
Weber, J. S. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785–792 (2017).
pubmed: 28068177
doi: 10.1200/JCO.2015.66.1389
Yoest, J. M. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 6, 73–82 (2017).
pubmed: 29067284
pmcid: 5644546
doi: 10.2147/ITT.S126227
Hu, W., Wang, G., Wang, Y., Riese, M. J. & You, M. Uncoupling therapeutic efficacy from immune-related adverse events in immune checkpoint blockade. iScience 23, 101580 (2020).
pubmed: 33083746
pmcid: 7554032
doi: 10.1016/j.isci.2020.101580
Abdel-Wahab, N., Shah, M. & Suarez-Almazor, M. E. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11, e0160221 (2016).
pubmed: 27472273
pmcid: 4966895
doi: 10.1371/journal.pone.0160221
Belkhir, R. et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann. Rheum. Dis. 76, 1747–1750 (2017).
pubmed: 28600350
doi: 10.1136/annrheumdis-2017-211216
Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
pubmed: 26765102
doi: 10.1016/j.ejca.2015.11.016
Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193–3198 (2015).
pubmed: 26282644
pmcid: 5087335
doi: 10.1200/JCO.2015.60.8448
Warner, B. M. et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24, 1259–1269 (2019).
pubmed: 30996010
pmcid: 6738284
doi: 10.1634/theoncologist.2018-0823
Carbonnel, F. et al. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin. Immunopathol. 39, 327–331 (2017).
pubmed: 28093620
doi: 10.1007/s00281-016-0613-x
Calabrese, L. H., Calabrese, C. & Cappelli, L. C. Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569–579 (2018).
pubmed: 30171203
doi: 10.1038/s41584-018-0074-9
Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).
pubmed: 34172516
pmcid: 8237720
doi: 10.1136/jitc-2021-002435
Jing, Y. et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat. Commun. 11, 4946 (2020).
pubmed: 33009409
pmcid: 7532211
doi: 10.1038/s41467-020-18742-9
Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
pubmed: 25399552
doi: 10.1056/NEJMoa1412082
Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918 (2015).
pubmed: 26115796
pmcid: 9004487
doi: 10.1016/S1470-2045(15)00083-2
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
pubmed: 27718847
doi: 10.1056/NEJMoa1606774
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407
pmcid: 4681400
doi: 10.1056/NEJMoa1504627
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
pubmed: 26412456
pmcid: 5705936
doi: 10.1056/NEJMoa1507643
Subudhi, S. K. et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc. Natl Acad. Sci. USA 113, 11919–11924 (2016).
pubmed: 27698113
pmcid: 5081579
doi: 10.1073/pnas.1611421113
Oh, D. Y. et al. Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 77, 1322–1330 (2017).
pubmed: 28031229
doi: 10.1158/0008-5472.CAN-16-2324
Lozano, A. X. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. https://doi.org/10.1038/s41591-021-01623-z (2022).
doi: 10.1038/s41591-021-01623-z
pubmed: 35840727
pmcid: 8866214
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
pubmed: 27806233
pmcid: 5247797
doi: 10.1056/NEJMoa1609214
Berner, F. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043–1047 (2019).
pubmed: 31021392
doi: 10.1001/jamaoncol.2019.0402
Läubli, H. et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology 7, e1386362 (2018).
pubmed: 29308309
doi: 10.1080/2162402X.2017.1386362
Kim, K. H. et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 9, 1722023 (2020).
pubmed: 32076579
pmcid: 6999841
doi: 10.1080/2162402X.2020.1722023
Grigoriou, M. et al. Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors. Cancer Immunol. Res. 9, 726–734 (2021).
pubmed: 33820810
pmcid: 7611354
doi: 10.1158/2326-6066.CIR-20-0969
Gonugunta, A. S. et al. Humoral and cellular correlates of a novel immune-related adverse event and its treatment. J. Immunother. Cancer 9, e003585 (2021).
pubmed: 34880115
pmcid: 8655605
doi: 10.1136/jitc-2021-003585
Reschke, R. et al. Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy. Int. J. Mol. Sci. 22, 8017 (2021).
pubmed: 34360781
pmcid: 8348898
doi: 10.3390/ijms22158017
Kim, S. T. et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat. Commun. 13, 1970 (2022).
pubmed: 35413951
pmcid: 9005525
doi: 10.1038/s41467-022-29539-3
Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655–671.e22 (2020).
pubmed: 32603654
pmcid: 7415717
doi: 10.1016/j.cell.2020.06.001
Wang, R. et al. High-dimensional analyses of checkpoint-inhibitor related arthritis synovial fluid cells reveal a unique, proliferating CD38hi cytotoxic CD8 T cell population induced by type I IFN [abstract]. Arthritis Rheumatol. 72 (Suppl. 10): abstract 1443 (2020).
Murray-Brown, W. et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J. Immunother. Cancer 8, e000281 (2020).
pubmed: 32571993
pmcid: 7311067
doi: 10.1136/jitc-2019-000281
Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715–720 (2018).
pubmed: 29309048
pmcid: 5785243
doi: 10.1172/JCI96798
Patel, A. J. et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat. Commun. 13, 3148 (2022).
pubmed: 35672305
pmcid: 9174492
doi: 10.1038/s41467-022-30863-x
de Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6–11 (2019).
pubmed: 30425107
doi: 10.1158/2326-6066.CIR-18-0245
Huang, Y.-T., Chen, Y.-P., Lin, W.-C., Su, W.-C. & Sun, Y.-T. Immune checkpoint inhibitor-induced myasthenia gravis. Front. Neurol. 11, 634 (2020).
pubmed: 32765397
pmcid: 7378376
doi: 10.3389/fneur.2020.00634
Kobayashi, T. et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J. Endocr. Soc. 2, 241–251 (2018).
pubmed: 29600292
pmcid: 5836529
doi: 10.1210/js.2017-00432
Mammen, A. L. et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann. Rheum. Dis. 78, 150–152 (2019).
pubmed: 30185415
doi: 10.1136/annrheumdis-2018-213777
Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
pubmed: 26380086
pmcid: 4570556
doi: 10.1186/s40425-015-0081-1
Lim, S. Y. et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin. Cancer Res. 25, 1557–1563 (2019).
pubmed: 30409824
doi: 10.1158/1078-0432.CCR-18-2795
Husain, B. et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J. Cancer Res. Clin. Oncol. 147, 1623–1630 (2021).
pubmed: 33837821
pmcid: 8076116
doi: 10.1007/s00432-021-03550-5
Wang, Y. N. et al. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol. Lett. 20, 611–622 (2020).
pubmed: 32565986
pmcid: 7285943
doi: 10.3892/ol.2020.11618
Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120, 63–68 (2019).
pubmed: 30377338
doi: 10.1038/s41416-018-0155-1
Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).
pubmed: 24695685
doi: 10.1126/scitranslmed.3008002
Cappelli, L. C., Dorak, M. T., Bettinotti, M. P., Bingham, C. O. & Shah, A. A. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology 58, 476–480 (2019).
pubmed: 30508191
doi: 10.1093/rheumatology/key358
Hasan Ali, O. et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer 107, 8–14 (2019).
pubmed: 30529903
doi: 10.1016/j.ejca.2018.11.009
Wölffer, M. et al. Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma. Cancers 14, 302 (2022).
pubmed: 35053465
pmcid: 8773840
doi: 10.3390/cancers14020302
Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).
pubmed: 26837003
pmcid: 4740747
doi: 10.1038/ncomms10391
Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021).
pubmed: 34239137
doi: 10.1038/s41591-021-01406-6
Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).
pubmed: 26633184
doi: 10.1001/jamaoncol.2015.4368
Lee, B. et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann. Oncol. 27, 1174–1177 (2016).
pubmed: 26861600
doi: 10.1093/annonc/mdw056
Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).
pubmed: 27687304
doi: 10.1093/annonc/mdw443
Gutzmer, R. et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur. J. Cancer 75, 24–32 (2017).
pubmed: 28214654
doi: 10.1016/j.ejca.2016.12.038
Danlos, F.-X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21–29 (2018).
pubmed: 29331748
doi: 10.1016/j.ejca.2017.12.008
Mitchell, E. L. et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur. J. Cancer 105, 88–102 (2018).
pubmed: 30439628
doi: 10.1016/j.ejca.2018.09.027
Richter, M. D. et al. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol. 70, 356–360 (2018).
pubmed: 29363290
doi: 10.1002/art.40397
Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905–1912 (2018).
pubmed: 29746230
pmcid: 6553840
doi: 10.1200/JCO.2017.77.0305
Kähler, K. C. et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol. Immunother. 67, 825–834 (2018).
pubmed: 29487980
doi: 10.1007/s00262-018-2134-z
Cortellini, A. et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist 24, e327–e337 (2019).
pubmed: 30796151
pmcid: 6656514
doi: 10.1634/theoncologist.2018-0618
Tison, A. et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 71, 2100–2111 (2019).
pubmed: 31379105
doi: 10.1002/art.41068
Martinez Chanza, N. et al. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J. Immunother. Cancer 8, e000538 (2020).
pubmed: 32217762
pmcid: 7174076
doi: 10.1136/jitc-2020-000538
Abu-Sbeih, H. et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J. Clin. Oncol. 38, 576–583 (2020).
pubmed: 31800340
doi: 10.1200/JCO.19.01674
Loriot, Y. et al. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur. J. Cancer 138, 202–211 (2020).
pubmed: 32905959
doi: 10.1016/j.ejca.2020.07.023
Efuni, E. et al. Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J. Clin. Rheumatol. 27, 267–271 (2021).
pubmed: 31977647
pmcid: 7374048
doi: 10.1097/RHU.0000000000001314
Hoa, S. et al. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol. Immunother. 70, 2197–2207 (2021).
pubmed: 33471137
doi: 10.1007/s00262-021-02851-5
Tully, K. H. et al. Risk of immune-related adverse events in melanoma patients with preexisting autoimmune disease treated with immune checkpoint inhibitors: a population-based study using SEER-medicare data. Am. J. Clin. Oncol. 44, 413–418 (2021).
pubmed: 34081033
doi: 10.1097/COC.0000000000000840
van der Kooij, M. K. et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study. Ann. Intern. Med. 174, 641–648 (2021).
pubmed: 33587686
doi: 10.7326/M20-3419
Bhatlapenumarthi, V., Patwari, A. & Harb, A. J. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J. Cancer Res. Clin. Oncol. 147, 2789–2800 (2021).
pubmed: 33774736
doi: 10.1007/s00432-021-03610-w
Yeung, C. et al. Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases. J. Immunother. 44, 362–370 (2021).
pubmed: 34121061
doi: 10.1097/CJI.0000000000000377
Panhaleux, M. et al. Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: a postmarketed phase IV safety assessment study. Eur. J. Cancer 160, 134–139 (2022).
pubmed: 34810048
doi: 10.1016/j.ejca.2021.10.018
Ansel, S., Rulach, R., Trotter, N. & Steele, N. Pembrolizumab for advanced non-small cell lung cancer (NSCLC): impact of autoimmune comorbidity and outcomes following treatment completion. J. Oncol. Pharm. Pract. https://doi.org/10.1177/10781552221079356 (2022).
doi: 10.1177/10781552221079356
pubmed: 35167399
Gulati, N. et al. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer Med. 10, 7457–7465 (2021).
pubmed: 34647433
pmcid: 8559502
doi: 10.1002/cam4.4239
Brown, L. J. et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J. Immunother. Cancer 9, e002121 (2021).
pubmed: 33963010
pmcid: 8108669
doi: 10.1136/jitc-2020-002121
Wu, C., Zhong, L., Wu, Q., Lin, S. & Xie, X. The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. Immunotherapy 13, 527–539 (2021).
pubmed: 33715386
doi: 10.2217/imt-2020-0230
Kostine, M. et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann. Rheum. Dis. 80, 36–48 (2021).
pubmed: 32327425
doi: 10.1136/annrheumdis-2020-217139
Klavdianou, K., Melissaropoulos, K., Filippopoulou, A. & Daoussis, D. Should we be afraid of immune check point inhibitors in cancer patients with pre-existing rheumatic diseases? Immunotherapy in pre-existing rheumatic diseases. Mediterr. J. Rheumatol. 32, 218–226 (2021).
pubmed: 34964025
pmcid: 8693295
doi: 10.31138/mjr.32.3.218
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H. & Hodi, F. S. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1607–1616 (2016).
pubmed: 27540850
doi: 10.1001/jamaoncol.2016.2453
Jaberg-Bentele, N. F., Kunz, M., Abuhammad, S. & Dummer, R. Flare-up of rheumatoid arthritis by anti-CTLA-4 antibody but not by anti-PD1 therapy in a patient with metastatic melanoma. Case Rep. Dermatol. 9, 65–68 (2017).
pubmed: 28611624
pmcid: 5465736
doi: 10.1159/000454875
Benson, Z., Gordon, S., Nicolato, P. & Poklepovic, A. Immunotherapy for metastatic melanoma with right atrial involvement in a patient with rheumatoid arthritis. Case Rep. Oncol. Med. 2017, 8095601 (2017).
pubmed: 29445556
pmcid: 5763099
Thomas, R., Patel, H. & Scott, J. Dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma. Cureus 13, e14387 (2021).
pubmed: 33981507
pmcid: 8106943
Montfort, A. et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin. Cancer Res. 27, 1037–1047 (2021).
pubmed: 33272982
doi: 10.1158/1078-0432.CCR-20-3449
Ghosh, N. et al. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J. Immunother. Cancer 10, e004008 (2022).
pubmed: 35091456
pmcid: 8804686
doi: 10.1136/jitc-2021-004008
Sakakida, T. et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin. Transl. Oncol. 22, 919–927 (2020).
pubmed: 31576495
doi: 10.1007/s12094-019-02214-8
Toi, Y. et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 5, 376–383 (2019).
pubmed: 30589930
doi: 10.1001/jamaoncol.2018.5860
Wang, D. et al. Immune-related adverse events predict the efficacy of immune checkpoint inhibitors in lung cancer patients: a meta-analysis. Front. Oncol. 11, 631949 (2021).
pubmed: 33732650
pmcid: 7958877
doi: 10.3389/fonc.2021.631949
Hussaini, S. et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors — a systematic review and meta-analysis. Cancer Treat. Rev. 92, 102134 (2021).
pubmed: 33302134
doi: 10.1016/j.ctrv.2020.102134
Teulings, H.-E. et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773–781 (2015).
pubmed: 25605840
doi: 10.1200/JCO.2014.57.4756
Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637–1644 (2000).
pubmed: 11104805
pmcid: 2193107
doi: 10.1084/jem.192.11.1637
Chapman, N. M. & Chi, H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55, 14–30 (2022).
pubmed: 35021054
pmcid: 8842882
doi: 10.1016/j.immuni.2021.12.012
Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872–2878 (2018).
pubmed: 30125216
doi: 10.1200/JCO.2018.79.0006
Strehl, C. & Buttgereit, F. Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol. Cell. Endocrinol. 380, 32–40 (2013).
pubmed: 23403055
doi: 10.1016/j.mce.2013.01.026
Fucà, G. et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4, e000457 (2019).
pubmed: 30964126
pmcid: 6435242
doi: 10.1136/esmoopen-2018-000457
Draghi, A. et al. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int. J. Cancer 145, 1408–1413 (2019).
pubmed: 30575963
doi: 10.1002/ijc.32080
Brown, P. M., Pratt, A. G. & Isaacs, J. D. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat. Rev. Rheumatol. 12, 731–742 (2016).
pubmed: 27784891
doi: 10.1038/nrrheum.2016.175
Downey, S. G. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13, 6681–6688 (2007).
pubmed: 17982122
pmcid: 2147083
doi: 10.1158/1078-0432.CCR-07-0187
Schadendorf, D. et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J. Clin. Oncol. 35, 3807–3814 (2017).
pubmed: 28841387
pmcid: 5791828
doi: 10.1200/JCO.2017.73.2289
Paz-Ares, L. G. et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 Trial. J. Thorac. Oncol. 17, 289–308 (2022).
pubmed: 34648948
doi: 10.1016/j.jtho.2021.09.010
Reck, M. et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open 6, 100273 (2021).
pubmed: 34607285
pmcid: 8493593
doi: 10.1016/j.esmoop.2021.100273
Waterhouse, D. M. et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J. Clin. Oncol. 38, 3863–3873 (2020).
pubmed: 32910710
pmcid: 7676888
doi: 10.1200/JCO.20.00131
Bilger, G. et al. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol. Immunother. https://doi.org/10.1007/s00262-021-03114-z (2021).
doi: 10.1007/s00262-021-03114-z
pubmed: 34821950
Chatzidionysiou, K., Liapi, M., Tsakonas, G., Gunnarsson, I. & Catrina, A. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors — is it time for a paradigm shift? Clin. Rheumatol. 40, 1687–1695 (2021).
pubmed: 32989505
doi: 10.1007/s10067-020-05420-w
Chen, A. Y., Wolchok, J. D. & Bass, A. R. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat. Rev. Rheumatol. 17, 213–223 (2021).
pubmed: 33686279
pmcid: 8366509
doi: 10.1038/s41584-021-00584-4
Bertrand, F. et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).
pubmed: 29273790
pmcid: 5741628
doi: 10.1038/s41467-017-02358-7
Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509–523.e6 (2022).
pubmed: 35537412
doi: 10.1016/j.ccell.2022.04.004
Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428–432 (2019).
pubmed: 31043740
doi: 10.1038/s41586-019-1162-y
Lesage, C. et al. Incidence and clinical impact of anti-TNFα treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit Survey. J. Immunother. 42, 175–179 (2019).
pubmed: 31090656
doi: 10.1097/CJI.0000000000000268
Wang, Y. et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J. Immunother. Cancer 6, 37 (2018).
pubmed: 29747688
pmcid: 5946546
doi: 10.1186/s40425-018-0346-6
Verheijden, R. J. et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry. Clin. Cancer Res. 26, 2268–2274 (2020).
pubmed: 31988197
doi: 10.1158/1078-0432.CCR-19-3322
Zou, F. et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J. Immunother. Cancer 9, e003277 (2021).
pubmed: 34789551
pmcid: 8601082
doi: 10.1136/jitc-2021-003277
Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer 8, e000842 (2020).
pubmed: 32581042
pmcid: 7312339
doi: 10.1136/jitc-2020-000842
Campochiaro, C. et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur. J. Intern. Med. 93, 87–94 (2021).
pubmed: 34391591
doi: 10.1016/j.ejim.2021.07.016
Weber, J. S. et al. 1040 O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Ann. Oncol. 32, S869 (2021).
doi: 10.1016/j.annonc.2021.08.1425
Lebbé, C. et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 Trial. J. Clin. Oncol. 37, 867–875 (2019).
pubmed: 30811280
pmcid: 6455714
doi: 10.1200/JCO.18.01998
Delyon, J. & Lebbe, C. IL-6 blockade in cancer patients treated with immune checkpoint blockade: a win-win strategy. Cancer Cell 40, 450–451 (2022).
pubmed: 35537409
doi: 10.1016/j.ccell.2022.04.010
Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264–iv266 (2018).
pubmed: 29917046
doi: 10.1093/annonc/mdy162
Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc. Netw. 17, 255–289 (2019).
pubmed: 30865922
doi: 10.6004/jnccn.2019.0013
Kennedy, L. C., Bhatia, S., Thompson, J. A. & Grivas, P. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J. Natl Compr. Canc. Netw. 17, 750–757 (2019).
pubmed: 31200356
doi: 10.6004/jnccn.2019.7310
Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073–4126 (2021).
pubmed: 34724392
doi: 10.1200/JCO.21.01440
Haanen, J. et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann. Oncol. 31, 724–744 (2020).
pubmed: 32194150
doi: 10.1016/j.annonc.2020.03.285
Michot, J.-M. et al. The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. Eur. J. Cancer 130, 39–50 (2020).
pubmed: 32172197
doi: 10.1016/j.ejca.2020.02.010
Naidoo, J. et al. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J. Natl Compr. Canc. Netw. 17, 712–720 (2019).
pubmed: 31200355
doi: 10.6004/jnccn.2018.7268
Calabrese, L. & Mariette, X. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. Ann. Rheum. Dis. 77, 162–164 (2018).
pubmed: 28928270
doi: 10.1136/annrheumdis-2017-212061
Nabel, C. S. et al. Anti-PD-1 immunotherapy-induced flare of a known underlying relapsing vasculitis mimicking recurrent cancer. Oncologist 24, 1013–1021 (2019).
pubmed: 31088979
pmcid: 6693726
doi: 10.1634/theoncologist.2018-0633
Yamada, T. et al. Non-small cell lung cancer treated by an anti-programmed cell death-1 antibody without a flare-up of preexisting granulomatosis with polyangiitis. Intern. Med. 58, 3129–3132 (2019).
pubmed: 31292396
pmcid: 6875450
doi: 10.2169/internalmedicine.3018-19
Maul, L. V., Weichenthal, M., Kähler, K. C. & Hauschild, A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J. Immunother. 39, 188–190 (2016).
pubmed: 27023060
doi: 10.1097/CJI.0000000000000118